Sol-Gel Technologies Ltd.
SLGLHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframePart of the healthcare sector, Sol-Gel Technologies Ltd. (SLGL) is listed under Biotechnology. At a $227.1M market cap, Sol-Gel Technologies Ltd. ranks as a micro-cap company within healthcare. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Market Cap
$227.1M
Beta
1.13
P/E (TTM)
—
P/E (Fwd)
-9.01
EPS (TTM)
$-5.58
EPS (Fwd)
$-7.70
ROE
-40.8%
ROA
-23.9%
Cash
$47.9M
Total Debt
$770,000
Free CF
-$2.1M
52W Change
190.3%
Annual Financials
Cash vs Debt
Where SLGL stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, SLGL finished 7.75% below its 150-day moving average ($76.35) and 2.01% above its 200-day moving average ($69.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLGL overbought or oversold?
At the September 3, 2026 close, SLGL's RSI(14) was 24.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $47.9M in cash comfortably exceeding the $770K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$2.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -40.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $3.9M (2022) to $19.4M (2025), reflecting a 399% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sol-Gel Technologies Ltd.'s trajectory.